OncoMatch

OncoMatch/Clinical Trials/NCT05315700

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Is NCT05315700 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ORIC-114 and Chemotherapy drug for solid tumors.

Phase 1/2RecruitingORIC PharmaceuticalsNCT05315700Data as of May 2026

Treatment: ORIC-114 · Chemotherapy drugThe purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Biomarker criteria

Required: EGFR exon 20 insertion mutation

EGFR exon 20 insertion mutation

Required: EGFR atypical mutation

atypical EGFR mutation

Required: HER2 (ERBB2) exon 20 insertion mutation

HER2 exon 20 insertion mutation

Required: HER2 (ERBB2) amplification

HER2 amplification as determined by an in situ hybridization (ISH) test

Required: HER2 (ERBB2) overexpression

HER2 overexpression as determined by an immunohistochemistry (IHC) test

Excluded: EGFR T790M

Known EGFR T790M mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

Kidney function

Liver function

Cardiac function

No history of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months

Adequate organ function; History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope · Duarte, California
  • City of Hope · Huntington Beach, California
  • City of Hope · Irvine, California
  • City of Hope · Long Beach, California
  • University of California, San Francisco · San Francisco, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify